Biotech fund llumina Accelerator invests in Genegoggle

Illumina, Inc. (NASDAQ: ILMN) has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator. The global company creation engine, focused on partnering with entrepreneurs to build breakthrough genomics startups, invested in four companies for the 3rd funding cycle of Illumina Accelerator Cambridge, UK and three companies for the 13th funding cycle of Illumina Accelerator San Francisco Bay Area.

“The global reach of Illumina Accelerator is demonstrated by our investment in these seven diverse startups from six countries,” said Amanda Cashin, PhD, co-founder and Global Head of Illumina For Startups.

Genegoggle Sp. z o.o. was among the chosen startups. It’s a biotech company from Poland, leverages multi-dimensional genomic and epigenetic elements to discover novel therapeutics and intelligent systems to improve human health.


Our privacy policy